Investor Login

Selventa Granted Patent for Discovery of Biomarker Profiles

Selventa Granted Patent for Discovery of Biomarker Profiles

 

CAMBRIDGE, Mass. – January 23, 2012 – Selventa™, a biomarker discovery company that enables personalized healthcare through stratification of patients based on disease-driving mechanisms, today announced that the U. S. Patent & Trademark Office has issued the Company U.S. Patent No 8,802,109, titled "Computer-aided Discovery of Biomarker Profiles in Complex Biological Systems." This patent, which was issued on December 20, 2011, relates to methods and techniques that facilitate discovery of biomarkers and thus aid in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.

Selventa / Uncategorized - 01/23/2012

Finding satisfaction in stratification

 

CAMBRIDGE, Mass., December 8, 2011 — Selventa, a personalized healthcare company focused on stratification of patients and development of predictive biomarker panels based on disease-driving mechanisms, recently formed a strategic scientific alliance with Linguamatics, a software solutions company that provides knowledge extraction through its I2E natural language processing (NLP) text-mining platform.

The idea is to combine the analytical capabilities of both companies to efficiently extract complex life science knowledge in a computable, structured, biological expression language format that can be used to interpret large-scale experimental data in the context of published literature.

Selventa / Uncategorized - 12/08/2011

Selventa Announces a Joint Technology Collaboration with Pfizer Inc., to Include Developing Knowledge-sharing Portal

 

CAMBRIDGE, Mass., March 28, 2011 --(BUSINESS WIRE)-- Selventa™ today announced a continuation and expansion of its strategic partnership with the world’s largest pharmaceutical company, Pfizer Inc., in the areas of biological knowledge dissemination and drug safety. The scope of the new collaboration, co-funded by Pfizer, includes creating a publicly available version of Selventa’s Biological Expression Language (BEL) and associated BEL Framework that will enable organizations to capture, store, combine and use scientific knowledge across a wide range of scientific applications to help inform and streamline decision-making regarding drug targets. The collaboration includes establishing a community of BEL stakeholders and users, and the development of a BEL community portal to disseminate the technology to the scientific community at large.

Selventa - 03/28/2011

Genstruct, Inc. changes name to Selventa as company launches re-branding effort

 

CAMBRIDGE, Mass. – November 30, 2010 - SelventaTM, which evolved from Genstruct®, Inc. today announced that it has changed its name and launched a re-branded website as part of an initiative to provide innovative solutions for its client partners. The company’s core strengths embrace a customer-focused approach that leverages existing patient data and innovative analytics to help pharmaceutical and biotechnology partners accelerate development and clarify decisions on therapeutics and diagnostics.

Selventa - 11/30/2010
logo_white
veteran_logo_white
NVCA
bio
nc-biotech